There are several types of hemophilia, a rare bleeding disorder wherein the blood fails to clot properly. Hemophilia A and B are the most common types, while hemophilia C is comparatively rare.
Search results for:
Hemophilia is a disorder wherein the blood is not able to clot properly. As a result, patients bleed easily, and it's unusually prolonged and heavy.
https://www.youtube.com/watch?v=pTIVORH7anc This video from Wochit News is all about a new treatment for severe hemophilia A. The Children’s Hospital of Los Angeles, California, has developed a breakthrough treatment that can reduce the bleeding episodes in people living with hemophilia A by up to 90 percent. MORE: Emicizumab shows…
An enzyme called activate protein C (APC), which prevents the formation of blood clots and therefore promotes bleeding could be targeted to treat hemophilia, suggests a study conducted by researcher at the University of Cambridge and the Children’s Hospital of Philadelphia.
Receiving a hemophilia diagnosis can leave patients and their caregivers with many unanswered questions about the disease. Many want to know how to find information, connect with other patients and families, and get support. Here are answers to some frequently asked questions about hemophilia: What is hemophilia?…
Hemophilia C is a rare bleeding disorder that affects the blood’s ability to clot.
Although no cure for hemophilia is currently available, a number of therapies can be used to control bleeding and other symptoms. These treatments can substantially increase life expectancy by lowering the risk of life-threatening complications such as bleeding in the brain, especially in people with severe hemophilia.
Hemophilia B is a rare genetic bleeding disorder that impairs the blood’s ability to clot properly.
My husband, Jared, had a knee bleed last week. The moment he felt the familiar twinge in his joint, he performed his usual treatment regimen: a factor infusion and bed rest. We thought we’d simply wait it out without doing anything special besides resting the injury…
SPK-8016, also known as RG6358, is an experimental gene therapy that was being investigated for hemophilia A patients who had developed neutralizing antibodies (inhibitors) against clotting factor VIII (FVIII).